Effect of Cancer Stage on Adverse Kidney Outcomes in Patients Receiving Immune Checkpoint Inhibitors for Melanoma

Wang, Qiyu; Strohbehn, Ian A.; Zhao, Sophia; Seethapathy, Harish; Strohbehn, Samuel D.; Hanna, Paul E; Lee, Meghan; Fadden, Riley; Sullivan, Ryan J.; Boland, Genevieve M.; Reynolds, Kerry L.; Sise, Meghan E.

doi:10.1016/j.ekir.2022.08.030

Cited by 2 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among patients who survived at least 4 years, nearly 20% reached the composite kidney disease outcome. Recently, we demonstrated that ICI‐AIN and chronic kidney disease risk is equivalent in patients with stage 3 or 4 melanoma receiving anti‐PD‐1 monotherapy, suggesting that patients with earlier‐stage cancer that receive ICIs will also have to be monitored for long‐term kidney impairment 32 …”

Section: Chronic Kidney Complications Of Icimentioning

confidence: 99%

Immunological mechanisms underlying clinical phenotypes and noninvasive diagnosis of immune checkpoint inhibitor‐induced kidney disease

Seethapathy

Mistry

Sise

2023

Immunological Reviews

Self Cite

View full text Add to dashboard Cite

SummaryImmune checkpoint inhibitors (ICIs) have become a mainstay of cancer therapy, with over 80 FDA‐approved indications. Used in a variety of settings and in combination with each other and with traditional chemotherapies, the hyperactive immune response induced by ICIs can often lead to immune‐related adverse events in bystander normal tissues such as the kidneys, lungs, and the heart. In the kidneys, this immune‐related adverse event manifests as acute interstitial nephritis (ICI‐AIN). In the era of widespread ICI use, it becomes vital to understand the clinical manifestations of ICI‐AIN and the importance of prompt diagnosis and management of these complications. In this review, we delve into the clinical phenotypes of ICI‐AIN and how they differ from traditional drug‐induced AIN. We also detail what is known about the mechanistic underpinnings of ICI‐AIN and the important diagnostic and therapeutic implications behind harnessing those mechanisms to further our understanding of these events and to formulate effective treatment plans to manage ICI‐AIN.

show abstract

Section: Chronic Kidney Complications Of Icimentioning

confidence: 99%